Canada markets closed

scPharmaceuticals Inc. (2SX.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
4.3200-0.0400 (-0.92%)
At close: 04:05PM CEST
Full screen
Previous Close4.3600
Open4.4600
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range4.3200 - 4.4600
52 Week Range4.0000 - 10.9000
Volume30
Avg. Volume0
Market Cap155.755M
Beta (5Y Monthly)0.09
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    scPharmaceuticals to Announce First Quarter 2024 Financial Results on Tuesday, May 14, 2024

    Management to host conference call and webcast at 4:30 p.m. ETBURLINGTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Tuesday, May 14th, 2024, to discuss the financial results

  • GlobeNewswire

    scPharmaceuticals Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of FUROSCIX Auto-Injector (furosemide 80mg/mL) Injection

    FUROSCIX Auto-injector being developed as a complement to the FUROSCIX On-body Infusor Company anticipates topline data in Q3 2024, followed by a Supplemental New Drug Application (sNDA) by year-end 2024, if successful BURLINGTON, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and

  • GlobeNewswire

    scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

    Generated 4Q 2023 net FUROSCIX® revenue of $6.1 million, at the upper end of the range provided in January and representing sequential growth of 61% from $3.8 million in 3Q 2023 Generated full-year net FUROSCIX® revenue of $13.6 million, at the upper end of the range provided in January Ended 2023 with cash, cash equivalents and short-term investments of $76 million Company to host investor conference call and webcast today, Wednesday, March 13, at 4:30pm ET BURLINGTON, Mass., March 13, 2024 (GL